Title:
抗腫瘍剤
Document Type and Number:
Japanese Patent JP5858391
Kind Code:
B2
Abstract:
Pharmaceuticals which are effective for treatment, prevention, and the like of cancer and have less side effects are disclosed. The antitumor agent of the present invention comprises as an effective ingredient at least one leukotriene inhibitor. Examples of the leukotriene inhibitor includes leukotriene production inhibitors and leukotriene receptor antagonists, and preferred specific examples of the leukotriene inhibitor include montelukast, zafirlukast, pranlukast, and zileuton; pharmaceutically acceptable salts of these compounds; and pharmaceutically acceptable solvates of these compounds and the salts. The leukotriene inhibitor can also be used as a relieving agent for pain accompanying a tumor(s), and as a stromal hyperplasia inhibitor.
Inventors:
Masao Sugamata
Application Number:
JP2015504803A
Publication Date:
February 10, 2016
Filing Date:
April 22, 2014
Export Citation:
Assignee:
Tochigi Clinical Pathology Institute Co., Ltd.
International Classes:
A61K31/404; A61K31/47; A61K31/41; A61P35/00
Domestic Patent References:
| JP2007514002A | 2007-05-31 | |||
| JP2003532675A | 2003-11-05 | |||
| JP2005519095A | 2005-06-30 |
Foreign References:
| WO2010115593A2 | 2010-10-14 |
Other References:
JPN6015024426; Ｋｅｉｏ Ｊ Ｍｅｄ． ５９（１）, 2010, １０-１８
JPN6015024428; Ａｒｔｅｒｉｏｓｃｌｅｒ Ｔｈｒｏｍｂ Ｖａｓｃ Ｂｉｏｌ． ２９（６）, 2009, ９１５-２０
JPN6015037649; Ｃｕｒｒｅｎｔ Ｒｅｓｐｉｒａｔｏｒｙ Ｃａｒｅ Ｒｅｐｏｒｔｓ １, 2012, ９-２０
JPN6015037652; ＣｌｉｎｉｃａｌＴｒｉａｌｓ．ｇｏｖ , 20120313, ＮＩＨ
JPN6015037656; 日呼吸会誌 ４２（５）, 2004, ３７８-８６
JPN6015024428; Ａｒｔｅｒｉｏｓｃｌｅｒ Ｔｈｒｏｍｂ Ｖａｓｃ Ｂｉｏｌ． ２９（６）, 2009, ９１５-２０
JPN6015037649; Ｃｕｒｒｅｎｔ Ｒｅｓｐｉｒａｔｏｒｙ Ｃａｒｅ Ｒｅｐｏｒｔｓ １, 2012, ９-２０
JPN6015037652; ＣｌｉｎｉｃａｌＴｒｉａｌｓ．ｇｏｖ , 20120313, ＮＩＨ
JPN6015037656; 日呼吸会誌 ４２（５）, 2004, ３７８-８６
Attorney, Agent or Firm:
Patent Service Corporation Tanigawa International Patent Office